Product Description
ARRY-382 (PF-07265804) is a selective inhibitor of colony-stimulating factor-1 receptor. (Sourced from: https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-21-3009/694376/ARRY-382-in-Combination-with-Pembrolizumab-in)
Mechanisms of Action: CSF-1R Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Pancreatic Cancer|Pancreatic Ductal Carcinoma|Ovarian Cancer|Colorectal Cancer|Adenocarcinoma
Phase 1: Osteolysis|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01316822 |
ARRAY-382-101 | P1 |
Completed |
Osteolysis|Colorectal Cancer |
2012-10-01 |
2020-09-21 |
Primary Endpoints|Treatments |
|
NCT02880371 |
ARRAY-382-201 | P2 |
Terminated |
Colorectal Cancer|Pancreatic Ductal Carcinoma|Ovarian Cancer|Pancreatic Cancer|Adenocarcinoma |
2019-09-17 |
12% |
2022-06-17 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/01/2023 |
PubMed |
In silico targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer. |
|
06/13/2022 |
PubMed |
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. |
|
11/09/2021 |
News Article |
OnKure Therapeutics Appoints Mark L. Boys, Ph.D., as Vice President of Discovery Chemistry |